Effectiveness of Sertraline in Treating Pathological Gamblers With a Diagnosis of Alcohol Dependence - 1

This study has been terminated.
(Terminated by the IRB for non-continuation)
Sponsor:
Collaborator:
Information provided by (Responsible Party):
New York State Psychiatric Institute
ClinicalTrials.gov Identifier:
NCT00249431
First received: November 3, 2005
Last updated: December 10, 2013
Last verified: April 2012
  Purpose

Pathological gamblers often are also dependent on alcohol and clinically depressed. Sertraline (Zoloft) is currently used to treat depression, panic disorder, and obsessive-compulsive disorder. The purpose of this trial is to determine the effectiveness of sertraline used in combination with relapse prevention therapy in decreasing gambling behavior and alcohol consumption in individuals with a diagnosis of pathological gambling and alcohol abuse or dependence.


Condition Intervention Phase
Alcoholism
Gambling
Drug: Sertraline
Behavioral: Relapse Prevention Therapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Pilot Study of Sertraline Plus Relapse Prevention Therapy (RP) for the Treatment of Pathological Gambling With Comorbid Abuse or Dependence

Resource links provided by NLM:


Further study details as provided by New York State Psychiatric Institute:

Primary Outcome Measures:
  • Decreased gambling behavior; measured throughout study by the Clinical Global Impression Scale. [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]

Enrollment: 9
Study Start Date: December 2001
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
Patients will be treated with Relapse Prevention Therapy plus placebo
Behavioral: Relapse Prevention Therapy
Patients will have a weekly one-hour session for medication evaluation, relapse prevention therapy and answer questionnaires.
Active Comparator: 2
Patients will be treated with Relapse prevention Therapy plus Sertraline.
Drug: Sertraline
Patients will be started on 25mg/day of Sertraline, and their dose will be increased to 50 mg/day by week two, and then weekly by 50mg/day based on clinical response and emergence of side effects. The maximum dose will be 200mg/day
Behavioral: Relapse Prevention Therapy
Patients will have a weekly one-hour session for medication evaluation, relapse prevention therapy and answer questionnaires.

Detailed Description:

Alcohol abuse and depression commonly occur in conjunction with pathological gambling. Sertraline (Zoloft) is a selective serotonin reuptake inhibitor (SSRI) currently used to treat depression, panic disorder, and obsessive-compulsive disorder. The purpose of this trial is to determine the effectiveness of sertraline combined with relapse prevention therapy in decreasing gambling behavior and alcohol abuse.

Participants in this 10-week trial will be randomly assigned to receive either relapse prevention (RP) therapy and sertraline or RP therapy and a placebo. Participants will begin taking 25 mg of either sertraline or placebo in a single morning dose for one week. If, after one week, participants do not show improvement, the dose will increase to 50 mg per day during Week 2, and will increase by 50 mg per day every week thereafter to a maximal dose of 200 mg per day.

Weekly hour-long study visits will include a medication evaluation, RP therapy, and questionnaires. In addition, evaluations at baseline, Week 5, and Week 10 will include pathological gambling and depression ratings, urine drug screens, and biochemical measures of alcohol consumption and liver function. All other weekly study visits will include evaluation of side effects, an interview on alcohol use, measures related to obsessive-compulsive drinking, and assessments of vital signs and concomitant medications.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Meets DSM-IV criteria for pathological gambling
  • Meets DSM-IV and SCID criteria for alcohol abuse or dependence
  • Medically healthy

Exclusion Criteria:

  • History of schizophrenia, schizoaffective disorder, or bipolar disorder
  • Current diagnosis of substance abuse or dependence, other than alcohol or nicotine
  • Current major depression
  • Currently suicidal
  • History of non-response to an adequate trial of sertraline, defined as 200 mg per day of sertraline for at least a 4-week period
  • Previous treatment with relapse prevention therapy for pathological gambling or alcohol dependence within the 3 months prior to study entry
  • Requires treatment with psychotropic medication
  • Unwilling to consent to a drug-free period, according to the following: 2 weeks of abstinence from antidepressant drugs, other than fluoxetine, buspirone, lithium, anticonvulsants, barbiturates, opiates, or benzodiazepines; 4 weeks of abstinence from clonazepam; 5 weeks of abstinence from fluoxetine
  • Clinically significant disorder, including kidney, pulmonary, cerebral vascular, cardiovascular, gastrointestinal, and endocrine disorders
  • Abnormal laboratory tests
  • Abnormal electrocardiogram
  • Pregnant or breastfeeding
  • Unwilling to use an adequate method of contraception for the duration of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00249431

Sponsors and Collaborators
New York State Psychiatric Institute
Investigators
Principal Investigator: Carlos Blanco, M.D. Columbia University
  More Information

No publications provided

Responsible Party: New York State Psychiatric Institute
ClinicalTrials.gov Identifier: NCT00249431     History of Changes
Other Study ID Numbers: #5156R, 5K23DA000482, 5 K23-DA000482-1, DPMCDA
Study First Received: November 3, 2005
Last Updated: December 10, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Alcoholism
Gambling
Alcohol-Related Disorders
Substance-Related Disorders
Mental Disorders
Impulse Control Disorders
Sertraline
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 20, 2014